Wipfli Financial Advisors’s Charles River Laboratories CRL Stock Holding History

Wipfli Financial Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$95K	Buy	+481	New	+$104K	0.01%	748

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Wipfli Financial Advisors's CRL Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Charles River Laboratories (CRL) in Q3 2022: 481 shares worth $95K. The stake represents 0.01% of the portfolio and ranks #748 among its holdings.

583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Wipfli Financial Advisors held 481 shares of Charles River Laboratories worth $95K as of Q3 2022.
Charles River Laboratories was a new Wipfli Financial Advisors position in Q3 2022.
Charles River Laboratories made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #748 holding.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.